The influence of OATP2B1 and atorvastatin on coproporphyrin isomers in rats.

Atorvastatin Coproporphyrin OATP2B1

Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 25 07 2023
revised: 04 09 2023
accepted: 11 09 2023
medline: 29 9 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Coproporphyrin I (CPI) and III (CPIII) are discussed as biomarkers for organic anion transporting polypeptides (OATPs). We report on CPI and CPIII levels in wildtype, rSlco2b1-knockout, and SLCO2B1-humanized rats at baseline and after administration of atorvastatin, an inhibitor of the CPIII-specific rOATP2B1/hOATP2B1 and the CPI/CPIII-transporting rOATP1B2. OATP-inhibition by atorvastatin leads to significantly increased CPI and CPIII serum levels. However, basal CP serum levels in rSlco2b1-knockout animals were significantly lower (CPI), or unaffected (CPIII). In the presence of atorvastatin, this genotype effect was abolished. In conclusion, our results indicate an unexpected impact of OATP2B1 on CP serum levels in rats.

Identifiants

pubmed: 37770158
pii: S1347-8613(23)00056-7
doi: 10.1016/j.jphs.2023.09.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

170-174

Informations de copyright

Copyright © 2023 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest There are no conflicts of interest to disclose for any of the authors.

Auteurs

Jonny Kinzi (J)

Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.

Markus Grube (M)

Center of Drug Absorption and Transport, Institute for Pharmacology, University Medicine Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.

Janine Hussner (J)

Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.

Isabell Seibert (I)

Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.

Matthias Hamburger (M)

Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.

Henriette E Meyer Zu Schwabedissen (HE)

Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland. Electronic address: h.meyerzuschwabedissen@unibas.ch.

Classifications MeSH